No Data
No Data
No Data
No Data
No Data
Genertec Universal Medical Unit to Raise Up to 2 Billion Yuan From Bond Issue
Genertec Universal Medical Group's (HKG:2666) unit China Universal Leasing is looking to raise up to 2 billion yuan from the issue of renewable corporate bonds in China, a Wednesday filing on the Hong
MT NewswiresApr 17 06:12 ET
Global Healthcare (02666) subsidiary plans to issue renewable corporate bonds of no more than 500 million yuan
Global Healthcare (02666) announced that China Global Leasing Co., Ltd. (issuer), a wholly-owned subsidiary of the company...
Zhitong FinanceApr 17 04:43 ET
China Post Securities: Endogenous growth is steady, and the Hong Kong stock healthcare services sector's valuation is highly attractive
Judging from the overall performance of medical service targets in Hong Kong stocks, with the exception of ICL's high revenue base in the early COVID-19 period, where dental revenue was affected by dental implant collection, most of the revenue from other medical service targets increased relatively well.
Zhitong FinanceApr 12 03:07 ET
Benign Growth For Genertec Universal Medical Group Company Limited (HKG:2666) Underpins Its Share Price
When close to half the companies in Hong Kong have price-to-earnings ratios (or "P/E's") above 10x, you may consider Genertec Universal Medical Group Company Limited (HKG:2666) as a highly attractive
Simply Wall StApr 2 19:43 ET
Genertec Universal Medical Group Clocks 7% Rise in 2023 Profit
Genertec Universal Medical Group's (HKG:2666) attributable net profit rose 7% in 2023 to 2.02 billion yuan from 1.89 billion yuan in 2022, according to a Hong Kong bourse filing on Wednesday. Earnings
MT NewswiresMar 27 02:05 ET
[Hong Kong Stock Connect] Global Healthcare (02666)'s profit increased 7% last year to $2,021 billion, and plans to distribute a final dividend of HK$0.35 per share
Jinwu Financial News | Global Healthcare (02666) announced that for the year ended December 31, 2023, the company's common equity holders should account for the annual profit of about RMB 2,021 billion (RMB, same below), an increase of 7.0% over the previous year; basic earnings per share were 1.07 yuan, compared with 1 yuan for the same period last year. A proposed final dividend of HK$0.35 per common share. During the period, revenue was approximately RMB 13.65 billion, an increase of 13.1% over the previous year. Among them, the healthcare business revenue was about 7.833 billion yuan, an increase of 22.9% over 2022, and the share of total revenue increased to 57.4%. During the period, the company achieved gross profit of 4
金吾財訊Mar 27 00:31 ET
No Data
No Data